Easy to read FDA package insert, drug facts, dosage and administration, and adverse effects for Tikosyn (Dofetilide). Dofetilide (Tikosyn) Considerations for Use*. US/FDA Special Notes. The patient must be registered to receive this drug; the hospital and pharmacy must. (dofetilide) product monograph and refers you to more detailed information in read the patient package insert and reread it each time therapy is renewed in.
|Published (Last):||11 June 2013|
|PDF File Size:||1.69 Mb|
|ePub File Size:||3.30 Mb|
|Price:||Free* [*Free Regsitration Required]|
Background Dofetilide is a class III antiarrhythmic agent approved for achieving and maintaining sinus rhythm in patients with symptomatic atrial fibrillation.
In 6 of the 8 patients, hydrochlorothiazide was discontinued during the hospital admission for dofetilide. Clinical Electrophysiology web site.
ECG was obtained before the initiation of therapy and 2 h after each dose and was monitored for QT dofetilide package insert prolongation. Background Dofetilide is a class III antiarrhythmic agent approved for achieving and maintaining sinus rhythm in patients with symptomatic atrial fibrillation.
Dofetilide – Tikosyn ® – Renal Dosing
Although it is ideal to stop or replace these medications with alternatives when starting dofetilide, it is not always possible. Am J Psychiatry[E-pub ahead of print]. JI Intervent Cardiac Electrophysiol In comparison to patients who were taking no other QT-prolonging medications, the odds of dofetilide package insert discontinuation was 1. Key Dofetilide package insert atrial dofrtilide.
These results suggest that dofetilide package insert incidence of discontinuation of dofetilide because of adverse events is much higher in dofetilide package insert real-world setting than has been reported in clinical trials. Dofetilide is a class III antiarrhythmic agent approved for achieving and maintaining sinus rhythm in patients with symptomatic atrial fibrillation.
Indeed, the most common cause dofrtilide acquired QT prolongation is exposure to QT-prolonging drugs, which act by blocking hERG-encoded potassium channels 24— Serum electrolytes, including potassium and magnesium, were monitored daily during the hospital stay and corrected as needed.
Conclusions The incidence of QT prolongation or VT that lead to discontinuation of dofetilide is remarkably dofetilide package insert in dofetilide package insert real-world setting than in clinical trials.
Concomitant use of dofetipide QT-prolonging drugs was associated with discontinuation of dofetilide. GFR glomerular filtration rate. Patients were categorized into 2 groups according to whether or not dofetilide was discontinued during the index hospitalization.
Figures in Article Figures. Study limitations Limitations of dofetilide package insert study include the following: However, neither study examined the factors associated with the discontinuation of dofetilide inserrt Pacing Clin Electrophysiol The incidence of QT prolongation or VT that lead to discontinuation of dofetilide is remarkably higher in the real-world setting dofetilide package insert in clinical trials.
Dofetilide, a class III antiarrhythmic drug, is frequently used for rhythm control in patients with AF.
Also, some additional information can be gleaned from retrospective observational studies published for other reasons. The majority of the concomitant QT-prolonging drugs in this study were antidepressants. There were no other differences between patients who discontinued versus those who were discharged on dofetilide. Patients who did not revert to sinus rhythm after 5 doses of dofetilide underwent electrical cardioversion dofetilde discharge.
Methods Study patients We conducted a retrospective cohort study of consecutive patients hospitalized for starting dofetilide to treat AF dofetilide package insert the Minneapolis Veterans Affairs Health Care System from to Go to top of page. However, the discontinuation rate of dofetilide is higher in cohort studies such as ours. The higher rate of dofetilide discontinuation in our cohort compared with other observational studies is likely from inclusion of patients who were taking other QT-prolonging drugs, which reflects the real-world experience The primary outcome variable was the discontinuation of dofetilide because of QTc prolongation dofetilide package insert VT.
Cookies are used by this site. Because of a risk of QT prolongation and VT, patients starting dofetilide need to be hospitalized for 3 days to closely monitor telemetry and electrocardiography.
The aim of this innsert was to dofetilide package insert the incidence and predictors of QT prolongation or VT leading to discontinuation of dofetilide in a real-world clinical setting.
One patient in whom dofetilide was discontinued for reasons other than QT prolongation or VT was excluded from the analysis. In large-scale population studies, AF has been associated with adverse cardiovascular events, including thromboembolism, heart failure, sudden cardiac death, dofetilide package insert cardiovascular mortality 4—6. Patients who were taking concomitant QT-prolonging drugs were 1.